RT Journal Article
SR Electronic
T1 Elevated mucosal antibody responses against SARS-CoV-2 are correlated with lower viral load and faster decrease in systemic COVID-19 symptoms
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.02.21250910
DO 10.1101/2021.02.02.21250910
A1 Fröberg, Janeri
A1 Gillard, Joshua
A1 Philipsen, Ria
A1 Lanke, Kjerstin
A1 Rust, Joyce
A1 van Tuijl, Diana
A1 Bousema, Teun
A1 Simonetti, Elles
A1 van der Gaast – de Jongh, Christa E.
A1 Bos, Mariska
A1 van Kuppeveld, Frank J.
A1 Bosch, Berend-Jan
A1 Nabuurs-Franssen, Marrigje
A1 van der Geest-Blankert, Nannet
A1 van Daal, Charlotte
A1 Huynen, Martijn A.
A1 de Jonge, Marien I.
A1 Diavatopoulos, Dimitri A.
YR 2021
UL http://medrxiv.org/content/early/2021/02/03/2021.02.02.21250910.abstract
AB Mucosal antibodies play a key role in protection against SARS-CoV-2 exposure, but their role during primary infection is not well understood. We assessed mucosal antibody responses during primary infection with SARS-CoV-2 and examined their relationship with viral load and clinical symptoms. Elevated mucosal IgM was associated with lower viral load. RBD and viral spike protein-specific mucosal antibodies were correlated with decreases in systemic symptoms, while older age was associated with an increase in respiratory symptoms. Up to 42% of household contacts developed SARS-CoV-2-specific mucosal antibodies, including children, indicating high transmission rates within households in which children might play an important role.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04590352Funding StatementThis study was funded by the Laboratory of Medical Immunology, Radboud university medical center.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the Arnhem-Nijmegen Medical Ethical Committee, is registered at clinicaltrials.gov (NCT04590352; ethical committee reference NL73418.091.20), and was performed in accordance with the declaration of Helsinki. Written informed consent was obtained from volunteers before any research procedure was initiated.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data and R-code that support the findings of this study are available from the corresponding author upon reasonable request.